Global HIV Drugs Market 2015-2019

HIV治療薬の世界市場2015-2019

◆タイトル:Global HIV Drugs Market 2015-2019
◆商品コード:IRTNTR7469
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年10月14日
◆ページ数:84
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、HIV治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、HIV治療薬の世界市場規模及び予測、市場シェア、種類別分析、地域別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About HIV
HIV is a type of retrovirus that causes infection in human beings. AIDS is a life-threatening disease caused by this virus. In this disease certain white blood cells (lymphocytes) are destroyed, resulting in the loss of the body’s ability to protect itself against infections. The major route of transmission of HIV infection is unprotected sex, contaminated needle, breast milk, and infected blood. HIV attacks the body’s white blood cells, specifically a subset called CD4 or helper T cells. The anti-retroviral therapy is used to treat the patient and help the immune system fight the infection. This is mainly used to keep the level of the HIV low in the body.

Technavio’s analysts forecast the global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019.

[Covered in this report]
This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection.

Based on the class of drugs, the market is segmented as follows:
• Multi-class combination products
• Nucleoside reverse transcriptase inhibitors
• Non-nucleoside reverse transcriptase inhibitors
• Protease inhibitors
• Fusion inhibitors
• Entry inhibitors – CCR5 co-receptor antagonist
• HIV integrase strand transfer inhibitors

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio’s report, Global HIV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• Bristol-Myers Squibb
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck

[Other prominent vendors]
• AbbVie
• AstraZeneca
• Boehringer Ingelheim
• Cipla
• Daiichi Sankyo
• Emcure
• F. Hoffmann-La Roche
• Hetero Drugs
• Mylan
• Pfizer
• Shionogi
• Teva Pharmaceutical Industries

[Market driver]
• Inflow of funds
• For a full, detailed list, view our report

[Market challenge]
• Patent expiries
• For a full, detailed list, view our report

[Market trend]
• Increasing public awareness
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 06: Market segmentation by drug class

PART 07: Global multi-class combination products market
Global multi-class combination products market

PART 08: Global nucleoside reverse transcriptase inhibitors market
Global nucleoside reverse transcriptase inhibitors market

PART 09: Global non-nucleoside reverse transcriptase inhibitors market
Global non-nucleoside reverse transcriptase inhibitors market

PART 10: Global protease inhibitors market
Global protease inhibitors market

PART 11: Global fusion inhibitors market
Global fusion inhibitors market

PART 12: Global entry inhibitors — CCR5 co-receptor antagonist market
Global entry inhibitors — CCR5 co-receptor antagonist market

PART 13: Global HIV integrase strand transfer inhibitors market
Global HIV integrase strand transfer inhibitors market

PART 14: Geographical segmentation
Global HIV drugs market segmentation by geography

PART 15: Market drivers
Increased funding
Rise in patient population
Unmet medical needs
Initiatives by governments

PART 16: Impact of drivers

PART 17: Market challenges
Expiry of patents
Associated social stigma
Side effects of drugs
Complications in disease diagnosis

PART 18: Impact of drivers and challenges

PART 19: Market trends
Rise in public awareness
Strategic alliances
Novel approaches

PART 20: US Government: Funding for HIV

PART 21: Vendor landscape
Competitive scenario
Market share analysis
Other prominent vendors

PART 22: Key vendor analysis
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck

PART 23: Appendix
List of abbreviations

PART 24: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global HIV drugs market 2014-2019 ($ millions)
Exhibit 03: Five forces analysis
Exhibit 04: Global HIV drugs market segmentation by drug class 2014
Exhibit 05: Global HIV drugs market segmentation by drug class 2014-2019 ($ millions)
Exhibit 06: Global multi-class combination products market 2014-2019 ($ millions)
Exhibit 07: Global nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
Exhibit 08: Global non-nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
Exhibit 09: Global protease inhibitors market 2014-2019 ($ millions)
Exhibit 10: Global fusion inhibitors market 2014-2019 ($ millions)
Exhibit 11: Global entry inhibitors — CCR5 co-receptor antagonist market 2014-2019 ($ millions)
Exhibit 12: Global HIV integrase strand transfer inhibitors market 2014-2019 ($ millions)
Exhibit 13: Global HIV drugs market segmentation by geography 2014
Exhibit 14: Global HIV drugs market segmentation by geography 2014-2019 ($ millions)
Exhibit 15: HIV drugs market in Americas 2014-2019 ($ millions)
Exhibit 16: HIV drugs market in EMEA 2014-2019 ($ millions)
Exhibit 17: HIV drugs market in APAC 2014-2019 ($ millions)
Exhibit 18: Assistance from donor governments for HIV treatment 2013
Exhibit 19: Global HIV statistics 2014
Exhibit 20: Impact of drivers
Exhibit 21: Impact of drivers and challenges
Exhibit 22: Funding by the US government for HIV 2010-2016 ($ billions)
Exhibit 23: Funding by the US government for domestic treatment and care of HIV 2010-2016 ($ billions)
Exhibit 24: Bristol-Myers Squibb: Revenue of Reyataz 2012-2014 ($ billions)
Exhibit 25: Bristol-Myers Squibb: Revenue of Sustiva 2012-2014 ($ billions)
Exhibit 26: Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
Exhibit 27: Gilead Sciences: Revenue of Truvada 2012-2014 ($ billions)
Exhibit 28: Gilead Sciences: Revenue of Emtriva 2012 and 2013 ($ millions)
Exhibit 29: Gilead Sciences: Revenue of Atripla 2012-2014 ($ billions)
Exhibit 30: Gilead Sciences: Revenue of Complera/Eviplera 2012-2014 ($ millions)
Exhibit 31: Gilead Sciences: Revenue of Viread 2012-2014 ($ millions)
Exhibit 32: GlaxoSmithKline: Revenue of Combivir 2012-2014 ($ millions)
Exhibit 33: GlaxoSmithKline: Revenue of Trizivir 2012-2014 ($ millions)
Exhibit 34: GlaxoSmithKline: Revenue of Agenerase and Lexiva 2012-2014 ($ millions)
Exhibit 35: GlaxoSmithKline: Revenue of Tivicay 2013-2014 ($ millions)
Exhibit 36: Johnson & Johnson: Revenue of Edurant 2012-2014 ($ millions)
Exhibit 37: Johnson & Johnson: Revenue of Prezista 2012-2014 ($ billions)
Exhibit 38: Merck: Revenue of Isentress 2012-2014 ($ billions)



【掲載企業】

Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, AstraZeneca, Boehringer Ingelheim, Cipla, Daiichi Sankyo, Emcure, F. Hoffmann-La Roche, Hetero Drugs, Mylan, Pfizer, Shionogi, Teva Pharmaceutical Industries.

【資料のキーワード】

HIV治療薬、AIDS、プロテアーゼ阻害剤、融合阻害剤、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[HIV治療薬の世界市場2015-2019] (Global HIV Drugs Market 2015-2019 / IRTNTR7469)販売に関する免責事項
[HIV治療薬の世界市場2015-2019] (Global HIV Drugs Market 2015-2019 / IRTNTR7469)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆